Bicara Therapeutics (BCAX) Free Cash Flow (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Free Cash Flow of -$37.6 million for Q1 2026, down 33.67% year-over-year from -$56.6 million in Q1 2025, and down 55.73% quarter-over-quarter from -$24.1 million in Q4 2025.
Bicara Therapeutics (BCAX) Free Cash Flow (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$37.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 33.67% year-over-year to -$37.6 million; the TTM figure through Mar 2026 stood at -$116.6 million (down 31.97% YoY), while the FY2025 annual figure was -$107.1 million, down 43.16% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$37.6 million, down from -$24.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$8.5 million in Q4 2023, with the low at -$37.6 million in Q1 2026.
- The 4-year median for Free Cash Flow is -$24.9 million (2025), against an average of -$22.8 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 254.96% in 2024, then advanced 19.78% in 2025.
- Bicara Therapeutics' Free Cash Flow stood at -$8.5 million in 2023, then plunged by 254.96% to -$30.1 million in 2024, then rose by 19.78% to -$24.1 million in 2025, then tumbled by 55.73% to -$37.6 million in 2026.
- Business Quant data shows BCAX's Free Cash Flow at -$37.6 million in Q1 2026, -$24.1 million in Q4 2025, and -$29.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | -44.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.27 Mn |
| Jun 30, 2026 | -44.27 Mn |
| Mar 31, 2026 | -37.57 Mn |
| Mar 31, 2026 | -37.57 Mn |
| Dec 31, 2025 | -24.12 Mn |
| Dec 31, 2025 | -24.12 Mn |
| Sep 30, 2025 | -29.29 Mn |
| Sep 30, 2025 | -29.29 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Mar 31, 2025 | -28.11 Mn |
| Mar 31, 2025 | -28.11 Mn |
| Dec 31, 2024 | -30.07 Mn |
| Dec 31, 2024 | -30.07 Mn |
| Sep 30, 2024 | -17.23 Mn |
| Sep 30, 2024 | -17.23 Mn |
| Jun 30, 2024 | -12.93 Mn |
| Jun 30, 2024 | -12.93 Mn |
| Mar 31, 2024 | -14.59 Mn |
| Mar 31, 2024 | -14.59 Mn |